FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057487103> ?p ?o ?g. }

• W2057487103 endingPage "e8617" @default.
• W2057487103 startingPage "e8617" @default.
• W2057487103 abstract "We conducted a Phase I dose escalation trial of ADVAX, a DNA-based candidate HIV-1 vaccine expressing Clade C/B' env, gag, pol, nef, and tat genes. Sequences were derived from a prevalent circulating recombinant form in Yunnan, China, an area of high HIV-1 incidence. The objective was to evaluate the safety and immunogenicity of ADVAX in human volunteers.ADVAX or placebo was administered intramuscularly at months 0, 1 and 3 to 45 healthy volunteers not at high risk for HIV-1. Three dosage levels [0.2 mg (low), 1.0 mg (mid), and 4.0 mg (high)] were tested. Twelve volunteers in each dosage group were assigned to receive ADVAX and three to receive placebo in a double-blind design. Subjects were followed for local and systemic reactogenicity, adverse events, and clinical laboratory parameters. Study follow up was 18 months. Humoral immunogenicity was evaluated by anti-gp120 binding ELISA. Cellular immunogenicity was assessed by a validated IFNgamma ELISpot assay and intracellular cytokine staining. ADVAX was safe and well-tolerated, with no vaccine-related serious adverse events. Local and systemic reactogenicity events were reported by 64% and 42% of vaccine recipients, respectively. The majority of events were mild. The IFNgamma ELISpot response rates to any HIV antigen were 0/9 (0%) in the placebo group, 3/12 (25%) in the low-dosage group, 4/12 (33%) in the mid-dosage group, and 2/12 (17%) in the high-dosage group. Overall, responses were generally transient and occurred to each gene product, although volunteers responded to single antigens only. Binding antibodies to gp120 were not detected in any volunteers, and HIV seroconversion did not occur.ADVAX delivered intramuscularly is safe, well-tolerated, and elicits modest but transient cellular immune responses.Clinicaltrials.gov NCT00249106." @default.
• W2057487103 created "2016-06-24" @default.
• W2057487103 creator A5004092087 @default.
• W2057487103 creator A5010176480 @default.
• W2057487103 creator A5015111622 @default.
• W2057487103 creator A5016493721 @default.
• W2057487103 creator A5020665252 @default.
• W2057487103 creator A5024507068 @default.
• W2057487103 creator A5027657945 @default.
• W2057487103 creator A5028187500 @default.
• W2057487103 creator A5029359442 @default.
• W2057487103 creator A5039272834 @default.
• W2057487103 creator A5043112987 @default.
• W2057487103 creator A5044410362 @default.
• W2057487103 creator A5044433515 @default.
• W2057487103 creator A5045476784 @default.
• W2057487103 creator A5047929823 @default.
• W2057487103 creator A5051195088 @default.
• W2057487103 creator A5051838716 @default.
• W2057487103 creator A5051979480 @default.
• W2057487103 creator A5053171428 @default.
• W2057487103 creator A5055534851 @default.
• W2057487103 creator A5077517503 @default.
• W2057487103 creator A5077928088 @default.
• W2057487103 creator A5082827056 @default.
• W2057487103 creator A5083515370 @default.
• W2057487103 creator A5034684542 @default.
• W2057487103 creator A5040339675 @default.
• W2057487103 creator A5052220709 @default.
• W2057487103 date "2010-01-25" @default.
• W2057487103 modified "2023-10-18" @default.
• W2057487103 title "Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine" @default.
• W2057487103 cites W1978584491 @default.
• W2057487103 cites W1984511743 @default.
• W2057487103 cites W1997047110 @default.
• W2057487103 cites W1999743248 @default.
• W2057487103 cites W2004936833 @default.
• W2057487103 cites W2032886698 @default.
• W2057487103 cites W2056267734 @default.
• W2057487103 cites W2064013993 @default.
• W2057487103 cites W2073557771 @default.
• W2057487103 cites W2075340091 @default.
• W2057487103 cites W2082179624 @default.
• W2057487103 cites W2083008217 @default.
• W2057487103 cites W2089687081 @default.
• W2057487103 cites W2095135796 @default.
• W2057487103 cites W2095302830 @default.
• W2057487103 cites W2097771941 @default.
• W2057487103 cites W2105323221 @default.
• W2057487103 cites W2149791183 @default.
• W2057487103 cites W2151658023 @default.
• W2057487103 cites W2153670011 @default.
• W2057487103 cites W2160663355 @default.
• W2057487103 cites W2162891851 @default.
• W2057487103 cites W2163415145 @default.
• W2057487103 doi "https://doi.org/10.1371/journal.pone.0008617" @default.
• W2057487103 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2799527" @default.
• W2057487103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20111582" @default.
• W2057487103 hasPublicationYear "2010" @default.
• W2057487103 type Work @default.
• W2057487103 sameAs 2057487103 @default.
• W2057487103 citedByCount "42" @default.
• W2057487103 countsByYear W20574871032012 @default.
• W2057487103 countsByYear W20574871032013 @default.
• W2057487103 countsByYear W20574871032014 @default.
• W2057487103 countsByYear W20574871032015 @default.
• W2057487103 countsByYear W20574871032017 @default.
• W2057487103 countsByYear W20574871032018 @default.
• W2057487103 countsByYear W20574871032019 @default.
• W2057487103 countsByYear W20574871032020 @default.
• W2057487103 countsByYear W20574871032021 @default.
• W2057487103 countsByYear W20574871032022 @default.
• W2057487103 countsByYear W20574871032023 @default.
• W2057487103 crossrefType "journal-article" @default.
• W2057487103 hasAuthorship W2057487103A5004092087 @default.
• W2057487103 hasAuthorship W2057487103A5010176480 @default.
• W2057487103 hasAuthorship W2057487103A5015111622 @default.
• W2057487103 hasAuthorship W2057487103A5016493721 @default.
• W2057487103 hasAuthorship W2057487103A5020665252 @default.
• W2057487103 hasAuthorship W2057487103A5024507068 @default.
• W2057487103 hasAuthorship W2057487103A5027657945 @default.
• W2057487103 hasAuthorship W2057487103A5028187500 @default.
• W2057487103 hasAuthorship W2057487103A5029359442 @default.
• W2057487103 hasAuthorship W2057487103A5034684542 @default.
• W2057487103 hasAuthorship W2057487103A5039272834 @default.
• W2057487103 hasAuthorship W2057487103A5040339675 @default.
• W2057487103 hasAuthorship W2057487103A5043112987 @default.
• W2057487103 hasAuthorship W2057487103A5044410362 @default.
• W2057487103 hasAuthorship W2057487103A5044433515 @default.
• W2057487103 hasAuthorship W2057487103A5045476784 @default.
• W2057487103 hasAuthorship W2057487103A5047929823 @default.
• W2057487103 hasAuthorship W2057487103A5051195088 @default.
• W2057487103 hasAuthorship W2057487103A5051838716 @default.
• W2057487103 hasAuthorship W2057487103A5051979480 @default.
• W2057487103 hasAuthorship W2057487103A5052220709 @default.
• W2057487103 hasAuthorship W2057487103A5053171428 @default.
• W2057487103 hasAuthorship W2057487103A5055534851 @default.
• W2057487103 hasAuthorship W2057487103A5077517503 @default.

• next